Clearance of defective muscle stem cells by senolytics reduces the expression of senescence-associated secretory phenotype and restores myogenesis in myotonic dystrophy type 1

Muscle weakness and atrophy are clinical hallmarks of myotonic dystrophy type 1 (DM1). Muscle stem cells, which contribute to skeletal muscle growth and repair, are also affected in this disease. However, the molecular mechanisms leading to this defective activity and the impact on the disease severity are still elusive. Here, we explored through an unbiased approach the molecular signature leading to myogenic cell defects in DM1. Single cell RNAseq data revealed the presence of a specific subset of DM1 myogenic cells expressing a senescence signature, characterized by the high expression of genes related to senescence-associated secretory phenotype (SASP). This profile was confirmed using different senescence markers in vitro and in situ. Accumulation of intranuclear RNA foci in senescent cells, suggest that RNA-mediated toxicity contribute to senescence induction. High expression of IL-6, a prominent SASP cytokine, in the serum of DM1 patients was identified as a biomarker correlating with muscle weakness and functional capacity limitations. Drug screening revealed that the BCL-XL inhibitor (A1155463), a senolytic drug, can specifically target senescent DM1 myoblasts to induce their apoptosis and reduce their SASP. Removal of senescent cells re-established the myogenic function of the non-senescent DM1 myoblasts, which displayed improved proliferation and differentiation capacity in vitro; and enhanced engraftment following transplantation in vivo. Altogether this study presents a well-defined senescent molecular signature in DM1 untangling part of the pathological mechanisms observed in the disease; additionally, we demonstrate the therapeutic potential of targeting these defective cells with senolytics to restore myogenesis

Autonomous Weapons Systems and the Regulation of War: Legal Perspectives and Practical Challenges from Belgium – Report on Belgium

The use of artificial intelligence (AI) in military armament comes with a large number of unparalleled opportunities, but also with a series of challenges, whether technical, ethical, political, or legal in nature. Whereas the legal challenges will be at the heart of this report, one cannot make abstraction of the other challenges as they are intimately intertwined and highly relevant for the legal questions. This particularly holds true for the technical capabilities of AI-driven weapons and their level of autonomy, especially regarding the control that would be left to humans concerning targeting decisions. Due to the progressive integration of autonomy in weapons, the role of the human operating such weapon seems to change from that of an ‘active controller’ to that of a ‘passive supervisor’. While it is generally agreed upon that ‘meaningful human control’ should remain at all time to ensure legal use and appropriate accountability, this control is, in practice, less obvious and increasingly difficult to uphold due to the speed of execution, the number of tasks to be accomplished, but also the complexity of these tasks. Moreover, the unpredictability resulting from the nature and design of these autonomous systems questions the role and impact of human control. For instance, in case of weapons with self-learning capabilities, the role of human actors is further reduced as the system learns by itself and develops new solutions to complex problems, without human intervention. In this report, we will start by presenting the Belgian political debate and legal approach to these complex issues, at both national and international level (I). Then, we will describe how this approach fits into the more general, domestic legal framework on the jus ad bellum (II) and the jus in bello (III). Lastly, we will analyse whether and how the general principles of criminal liability can be applied (IV)

Neonatal hyperoxia leads to white adipose tissue remodeling and susceptibility to hypercaloric diet

Abstract Individuals born preterm are at higher risk of cardiovascular and metabolic diseases in adulthood, through mechanisms not completely understood. White adipose tissue in humans and rodents is a dynamic endocrine organ and a critical player in the regulation of metabolic homeostasis. However, the impact of preterm birth on white adipose tissue remains unknown. Using a well‐established rodent model of preterm birth‐related conditions in which newborn rats are exposed during postnatal days 3–10 to 80% of oxygen, we evaluated the impact of transient neonatal hyperoxia on adult perirenal white adipose tissue (pWAT) and liver. We further assessed the effect of a second hit with a high‐fat high‐fructose hypercaloric diet (HFFD). We evaluated 4‐month‐old adult male rats after 2 months of HFFD. Neonatal hyperoxia led to pWAT fibrosis and macrophage infiltration without modification in body weight, pWAT weight, or adipocyte size. In animals exposed to neonatal hyperoxia vs. room air control, HFFD resulted in adipocyte hypertrophy, lipid accumulation in the liver, and increased circulating triglycerides. Overall, preterm birth‐related conditions had long‐lasting effects on the composition and morphology of pWAT, along with a higher susceptibility to the deleterious impact of a hypercaloric diet. These changes suggest a developmental pathway to long‐term metabolic risk factors observed clinically in adults born preterm through programming of white adipose tissue

Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1

Abstract Muscle stem cells, the engine of muscle repair, are affected in myotonic dystrophy type 1 (DM1); however, the underlying molecular mechanism and the impact on the disease severity are still elusive. Here, we show using patients’ samples that muscle stem cells/myoblasts exhibit signs of cellular senescence in vitro and in situ. Single cell RNAseq uncovers a subset of senescent myoblasts expressing high levels of genes related to the senescence-associated secretory phenotype (SASP). We show that the levels of interleukin-6, a prominent SASP cytokine, in the serum of DM1 patients correlate with muscle weakness and functional capacity limitations. Drug screening revealed that the senolytic BCL-XL inhibitor (A1155463) can specifically remove senescent DM1 myoblasts by inducing their apoptosis. Clearance of senescent cells reduced the expression of SASP, which rescued the proliferation and differentiation capacity of DM1 myoblasts in vitro and enhanced their engraftment following transplantation in vivo. Altogether, this study identifies the pathogenic mechanism associated with muscle stem cell defects in DM1 and opens a therapeutic avenue that targets these defective cells to restore myogenesis